Introduction {#Sec1}
============

Children with many forms of congenital heart disease (CHD) are prone to develop postoperative elevation in pulmonary vascular resistance (PVR) \[[@CR1]\]. Resultant pulmonary hypertension (PH) may complicate the postoperative course \[[@CR2]\]. PH may develop after cardiopulmonary bypass due to injury or transient dysfunction of the pulmonary endothelium \[[@CR3]\]. Several therapies are currently used for postoperative PH \[sedation, alkalosis, inhaled nitric oxide (iNO), intravenous prostacyclins, adenosine, and others\] \[[@CR4]\]. However, intravenous prostacyclins \[[@CR5]\] may cause systemic hypotension, and although iNO appears selective for the pulmonary vasculature, the drug is costly, deliverable only as a gas, and may be associated with rebound PH during withdrawal \[[@CR6]\]. A fast-acting, pulmonary-selective, easily administered agent that is safe and without a rebound effect is needed.

Sildenafil acts by inhibiting phosphodiesterase type 5 (PDE5), an enzyme that hydrolyzes intracellular cyclic guanosine monophosphate (cGMP) to 5′-GMP \[[@CR7]\] and is highly expressed in the lungs \[[@CR8]\]. Oral sildenafil received approval for treatment of PH after a double-blind, placebo-controlled trial showed it to be an effective treatment of chronic PH in adults \[[@CR9]\]. In pediatric patients undergoing heart surgery, oral sildenafil attenuated rebound PH after iNO withdrawal during the early postoperative period \[[@CR10], [@CR11]\]. However, when administered enterally, the bioavailability of sildenafil is only about 40% in healthy subjects \[[@CR12]\]. Critically ill children in the postoperative setting may have unpredictable enteral absorption \[[@CR13]\], such that intravenous sildenafil may be more appropriate. Although preliminary studies in children with intravenous sildenafil report lower pulmonary arterial pressure (PAP) and PVR after cardiac surgery or during cardiac catheterization \[[@CR14], [@CR15]\], the optimal dose and the potential adverse effects remain undetermined, and little information is available on the effect of sildenafil on mortality and morbidity.

A clinical trial was designed to assess the efficacy, safety, and resource utilization of intravenous sildenafil in PH that developed during the postoperative period in children undergoing corrective congenital heart surgery. Although the trial was stopped due to slow accrual of patients, 17 patients were randomized and treated. The results from these patients are reported herein.

Materials and methods {#Sec2}
=====================

Study design {#Sec3}
------------

From October 2003 to January 2005, a randomized, multicenter, double-blind, placebo-controlled, dose-ranging, parallel-group study was conducted in children undergoing corrective cardiac surgery who developed postoperative PH. Patients were randomized to one of three doses of intravenous sildenafil, or placebo, for a minimum of 24 h.

The study was conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practices guidelines. The study protocol was reviewed and approved by the local institutional ethics committees. Patients believed to be at high risk for developing postoperative PH were identified before surgery. Written informed consent was obtained prior to initiation of protocol-specified procedures from each patient's parent or legal guardian, and patient consent was obtained (when applicable) within the 2 weeks before surgery.

Eligibility {#Sec4}
-----------

All infants or children aged 0 (≥34 weeks gestational age) to 17 years undergoing corrective cardiac surgery with a clinical diagnosis of postoperative PH within 48 h of the end of surgery and systolic PAP \>50% of systolic arterial blood pressure (\>75% for neonates ≤28 days) were eligible (Fig. [1](#Fig1){ref-type="fig"}). PH was confirmed by Doppler echocardiogram using the modified Bernoulli equation to the peak velocity of tricuspid regurgitation \[*p* = 4*v*^2^, where *p* = peak pressure drop from the right ventricle to the right atrium and *v* = peak velocity of tricuspid regurgitation (m/s)\] that has been correlated with invasive transcatheter measurements \[[@CR8]\], or pulmonary artery (PA) catheter at baseline. The exclusion criteria included: use of postoperative treatment solely for the purpose of treating or preventing PH, including agents used at relatively high doses for the purpose of deep/heavy sedation, such as fentanyl; agents used for continued paralysis, such as pancuronium (except when used to manage clinical situations such as open chest or critical airway); alkalinization by methods such as hyperventilation (pCO~2~ \<30 mmHg) or bicarbonate (HCO~3~) infusion; vasodilators; meeting the criteria for extracorporeal membrane oxygenation (ECMO); receipt of concomitant nitrates or NO donors, open-label sildenafil within 48 h prior to surgery or any time postoperatively; supplemental arginine, long-acting α-blockers, endothelin antagonists (e.g., bosentan), or potent cytochrome P450 3A4 inhibitors such as ritonavir or nicorandil. Additional exclusion criteria were: occurrence of postoperative complications that resulted in hypoxemia (other than PH) due to lung disease; serious postoperative bleeding resulting in hypotension; impaired renal function \[serum creatinine \>2.5 times the upper limit of normal (ULN)\] or hepatic function (alanine transaminase or aspartate transaminase \>3.0 ULN; conjugated bilirubin \>2.0 ULN; total bilirubin \>2.0 ULN); and leukopenia (WBC \<2,500/μl). Permitted medications included inotropes, milrinone, and other medication used to treat congestive heart failure.Fig. 1Study profile. *PAP* pulmonary arterial pressure, *SBP* systolic blood pressure. \*One patient withdrawn before treatment

Randomization {#Sec5}
-------------

The patients, parents, all clinical staff, and the investigators were blinded to study drug allocation. An automated interactive voice response system was used to assign patients to treatment. Randomization was stratified by age (neonate or non-neonate) and by study center to ensure a balance across treatment groups. The minimization approach with biased coin assignment was used for stratification. The sponsor (Pfizer Inc.) provided 50-ml vials containing sildenafil 1.0 mg/ml. Placebo was provided as bags of 5% dextrose in water. The research pharmacist or other qualified individual received the randomized treatment assignment and prepared the bolus dose and maintenance infusion. The dilution was calculated according to the patient's weight such that the assigned concentration (low, medium, or high) was infused at the same rate for all patients of a particular weight so that the staff remained blinded to the study dose.

Protocol {#Sec6}
--------

Baseline echocardiograms were performed to verify the presence of PH. Baseline hemodynamic parameters (in patients with a pulmonary artery, left atrial, and/or right atrial/central venous catheter), inotrope score \[[@CR16]\], and vital signs were measured, and blood samples were collected for serum lactate measurement. Final study assessments were performed at discharge or 7 days after study drug infusion, whichever occurred first. There was a follow-up telephone call 28 days after study drug infusion.

Three intravenous sildenafil dosage regimens were selected to achieve target sildenafil plasma concentrations of approximately 40, 120, and 360 ng/ml in the low-, medium-, and high-dose groups, respectively. Selection of sildenafil doses for neonates and infants \<60 days of age was to be based on pharmacokinetic data in neonates obtained from a clinical trial that was ongoing at the time \[[@CR17], [@CR18]\]. Each intravenous sildenafil dose regimen consisted of a bolus loading dose infused over 5 min followed immediately by a maintenance infusion over 24--72 h (Supplementary Table 2). After 30 min of study drug infusion, additional therapy for PH was to be initiated if clinically indicated based on protocol-defined rules (see Supplementary Material). If the patient was judged clinically stable at 24 h or longer after randomization, the infusion was discontinued. The infusion of study drug continued for a minimum of 24 and maximum of 72 h.

Pharmacokinetics {#Sec7}
----------------

Plasma sample extracts were analyzed using liquid chromatography and tandem mass spectrometry for separation and detection of the analytes. The overall method imprecision values for the analysis of plasma quality control samples at concentrations of 3, 30, and 350 ng/ml were 6.2%, 4.5%, and 6.1%, respectively, for sildenafil.

Statistics {#Sec8}
----------

Data are expressed as mean ± standard deviation (SD) if normally distributed or as median (range). Comparisons between groups were made with independent *t* tests and Wilcoxon tests for continuous variables, exact log-rank tests for times to event, and chi-square tests for frequencies. A *p* value \<0.05 was considered significant.

Assuming that 75% of the placebo patients and 40% of patients at the highest sildenafil dose would require additional therapy within 24 h of the start of infusion, a sample size of 228 patients (57 per treatment arm) was required to detect this difference with 90% power with a one-sided type I error rate of 0.025 (corresponding to a two-sided level of 0.05), using a Hochberg adjustment for multiple comparisons that results in the minimum one-sided per-comparison error rate of 0.0085. Allowing for a postrandomization withdrawal rate of 10%, 252 patients were required to be randomized.

Endpoints {#Sec9}
---------

The primary endpoint was the receipt of any additional therapy for treatment of postoperative PH within 24 h of start of study drug infusion. The secondary endpoints were duration of mechanical ventilation and length of postoperative hospital stay. Tertiary endpoints included total duration of administration of additional therapy for PH, change from baseline in postoperative inotrope scores at postbaseline assessment times, length of stay in an intensive care unit (ICU), and deaths within 28 days of follow-up or during hospital stay. Also, change from baseline in serum lactate levels and change from baseline in hemodynamic parameters (PAP, left atrial, right atrial/central venous pressure) were determined.

Results {#Sec10}
=======

Twenty-seven centers worldwide participated in the study, but only six centers in France and the USA randomized patients. The sponsor terminated the study after 15 months owing to slow patient accrual. Of 87 patients screened who provided informed consent, 18 (21%) had postoperative PH and were randomized. No neonates and infants less than 60 days old were enrolled because sildenafil dosing for these patients remained undetermined. One patient was withdrawn before treatment. The subsequent analysis was performed on the remaining 17 treated patients (Fig. [1](#Fig1){ref-type="fig"}).

Patient characteristics {#Sec11}
-----------------------

The median age and weight were 5 months (range 3 months--14 years), and 5.2 kg (range 3.9--60 kg), respectively. There were eight females (Table [1](#Tab1){ref-type="table"}). Seven had Down syndrome. Five patients received placebo, and four patients each received low-, medium-, and high-dose intravenous sildenafil (Fig. [1](#Fig1){ref-type="fig"}). The types of lesions are presented in Table [1](#Tab1){ref-type="table"}.Table 1Patient characteristicsCharacteristic*n*Males/females9/8Age \>2 months to 2 years15 \>2--12 years1 \>12--17 years1Cardiac lesions recorded at screening Ventricular septal defect only4 Atrial septal defect, primum type1 Atrioventricular canal, complete7 Regurgitant aortic or mitral valve requiring valvuloplasty or replacement3 Left heart obstruction with two fully developed ventricles, including mitral stenosis requiring valvuloplasty or replacement, supravalvular mitral stenosis, aortic stenosis1 Truncus arteriosus1

Efficacy of sildenafil {#Sec12}
----------------------

Additional therapy after 30 min of protocol infusion and within the first 24 h was required by 2 of 5 (40%) placebo-treated and 2 of 12 (17%) sildenafil-treated patients (all doses combined, *p* = 0.330). No patient from the intravenous sildenafil high-dose group received additional therapy within 24 h of start of study drug. Nitric oxide was the most frequently received additional therapy. Median time to extubation was shorter for patients on sildenafil compared with placebo: 3 days (range 1--11 days) versus 8 days (range 4--11 days, *p* = 0.023; log rank) (Fig. [2](#Fig2){ref-type="fig"}a). Median time to first discharge from the hospital was 12 days in the sildenafil group and 21 days in the placebo group (*p* = 0.135) (Fig. [2](#Fig2){ref-type="fig"}b). Median time to first discharge from the ICU was shorter for sildenafil patients: 6 days (range 1--12 days) versus 15 days (range 5--15 days, *p* = 0.008) (Fig. [2](#Fig2){ref-type="fig"}c).Fig. 2Kaplan--Meier analysis of **a** time to extubation, **b** time to intensive care unit discharge, and **c** length of hospital stay for patients in the placebo group versus those in the combined sildenafil group

During the first 4 h of treatment, reduction in systolic PAP and mean PAP (mean ± SD) was greater with sildenafil than placebo: 46 ± 11 to 35 ± 6 mmHg versus 49 ± 12 to 49 ± 17 mmHg (*p* = 0.027) and 33 ± 10 to 23 ± 5 mmHg versus 37 ± 10 to 36 ± 15 mmHg (*p* = 0.055), respectively (Fig. [3](#Fig3){ref-type="fig"}, Supplementary Fig. 4). Reduction in diastolic PAP did not differ by treatment (21 ± 12 to 13 ± 7 mmHg versus 27 ± 11 to 15 ± 5 mmHg, *p* = 0.306) (Supplementary Fig. 4). Only minor reductions in systemic systolic and diastolic blood pressure were observed: 82 ± 14 to 79 ± 13 mmHg versus 72 ± 15 to 73 ± 11 mmHg (*p* = 0.658) and 49 ± 9 to 45 ± 7 mmHg versus 47 ± 9 to 43 ± 14 mmHg (*p* = 0.813), respectively (Fig. [3](#Fig3){ref-type="fig"}, Supplementary Fig. 4).Fig. 3Systolic blood pressure (SBP) and systolic pulmonary arterial pressure (SPAP) during first 4 h of drug infusion for patients in the placebo group versus those in the combined sildenafil group

Other outcome measures {#Sec13}
----------------------

Eight of 17 treated patients, 5 on sildenafil (42%) and 3 on placebo (60%), received additional therapy up to day 28 of the follow-up. Last postbaseline serum lactate values ranged from 0.5 to 1.92 mmol/l (median 1.02 mmol/L) in the three sildenafil groups, and from 1.0 to 2.31 mmol/l (median 1.2 mmol/l) in the placebo group (*p* = 0.874). Similarly, the last postbaseline total inotrope score did not differ between sildenafil groups (median 10, range 5--32) and placebo (median 11.5, range 5--24.5; *p* = 0.909).

Safety {#Sec14}
------

Adverse events were reported in 15 (88.2%) patients; none were treatment related.

No patients experienced significant hemodynamic compromise while on sildenafil infusion. There were no differences in mean arterial, left atrial, and central venous pressure between placebo and sildenafil patients. No patient experienced a clinically relevant decrease in oxygenation as measured by pulse oximetry and reported as an adverse event during infusion of study drug.

Four patients died. Two patients died before randomization and the cause of death was related to their congenital heart disease. Two additional patients from the placebo group died after randomization. One 6-month-old female with Down syndrome and ventricular septal defect experienced respiratory distress 19 days after surgical closure of the defect. The second postoperative death occurred in a 14-year-old male who experienced a complicated postoperative course after mitral valve repair with refractory PH and eventually died from fungal sepsis on postoperative day 64.

Discussion {#Sec15}
==========

In the present study, intravenous sildenafil lowered PAP and decreased morbidity by shortening the time to extubation and length of ICU stay in a small pediatric population sample undergoing corrective heart surgery. Despite the benefit of early correction and improvements with intra- and postoperative care, postoperative PH still occurs. In a recent survey, an estimated 2% of pediatric patients undergoing congenital heart surgery experienced severe postoperative PH \[[@CR19]\]. In our study, we found that, in a selected pediatric population considered at risk for PH, 21% experienced postoperative PH.

Interestingly, a high proportion (7 out of 17) of our study patients had Down syndrome. It is well known that patients with Down syndrome exhibit an abnormal propensity for postoperative PH after congenital heart surgery. Patients with Down syndrome are readily overrepresented in studies of postoperative PH, accounting for 44--60% of cases \[[@CR15], [@CR19]\]. Specific features associated with PH in Down syndrome include alveolar hypoplasia and thickness of small pulmonary arteries \[[@CR20]\]. To date, no specific study has addressed use of sildenafil in postoperative PH associated with Down syndrome. However, management and treatment of such patients with pulmonary vasodilators do not differ and carry results similar to those of comparable patients without chromosomal aberrations \[[@CR19]\]. Finally, the true incidence of postoperative PH may be underestimated in this study for the following reasons: first, some patients with life-threatening postoperative PH were emergently treated with pulmonary vasodilators or ECMO and could not be randomized to the study; second, neonates and infants aged \<60 days, traditionally accounting for the majority of postoperative PH cases (particularly following repair of transposition of the great arteries, truncus arteriosus, and total anomalous pulmonary venous drainage) \[[@CR19], [@CR20]\], were not included.

Four deaths were reported, two before randomization and two in the placebo group, suggesting that children potentially at risk for postoperative PH in the present study represent an at-risk population for congenital heart surgery. However, the risk of postoperative PH cannot be ascertained from this small and selected population sample. Nevertheless, postoperative PH still carries significant morbidity and even mortality. In a recent study, among 100 patient deaths after congenital heart surgery, PH was the fifth most frequent etiology, accounting for 8% of the deaths \[[@CR21]\]. This is also in agreement with the results of Lindberg and colleagues, who reported 7.4% mortality within 30 days postoperatively, and 11% mortality within 1 year in children who underwent cardiac operations and had severe postoperative PH, despite the use of specific therapy, including iNO \[[@CR19]\]. This further emphasizes the need for an optimal strategy to anticipate and treat postoperative PH.

Our results show that intravenous sildenafil effectively decreased systolic PAP. However, oral sildenafil is also often effective \[[@CR9]--[@CR11]\], despite unpredictable bioavailability \[[@CR12]\]. Diminished visceral blood flow and gastrointestinal motility as well as use of opioids can reduce the absorption of sildenafil, especially after cardiopulmonary bypass. Whether the intravenous form is potentially more effective than oral administration remains undetermined. Similarly, we cannot conclude from the present study if the intravenous form is associated with more frequent adverse events.

Unlike previous reports investigating intravenous sildenafil after pediatric cardiac surgery \[[@CR14], [@CR15], [@CR22]\], this is the first study to explore sildenafil as an initial treatment for nonacute postoperative PH. The use of a bolus followed by a maintenance dose for a maximum of 72 h was specifically designed to treat postoperative PH. The administration of intravenous sildenafil at any dose was not associated with any clinically relevant adverse events. No significant systemic vasodilatation occurred compared with placebo. The results indicate that intravenous sildenafil, administered as a bolus dose followed by a maintenance dose, seems well tolerated in this patient population.

The major limitation of this study was the premature closure of the trial, prompted by slow accrual of patients with demonstrable PH. Contributing to the slow accrual was the exclusion of patients who were emergently treated with a pulmonary vasodilator or ECMO and of neonates and infants aged \<60 days, who were not included. Of the patients enrolled preoperatively, 21% had significant untreated PH upon reaching the postoperative ICU. Consequently, 1,086 patients would have needed to be enrolled to achieve the sample size estimate of 228. Given the known difficulties in executing pediatric trials and the slow accrual rate (18 patients in 15 months), the original assumptions made the target enrollment number appear unattainable. However, in retrospect, the treatment effect was larger than anticipated, so that a positive trial may have been seen with far fewer patients. These observations may have important bearing on planning future studies on postoperative PH. Nonetheless, with such a limited number of patients, we could not show convincing efficacy, nor could we determine the optimal intravenous sildenafil dose. However, the absence of any clinically relevant adverse events associated with its efficacy on PAP (including any important change in continuously monitored pulse oximetry) suggests that use of intravenous sildenafil is relatively safe at the three doses we used. The absence of clinically relevant hypoxemia suggests that the potential adverse impact on intrapulmonary shunt was not clinically significant, although the fact that blood gas measurements and arterial PO~2~ were not regularly recorded represents a significant study limitation in this regard. No firm conclusion can be made about the impact of intravenous sildenafil on gas exchange. Further studies are needed to determine the optimal dose needed to decrease pulmonary vascular resistance while still avoiding significant adverse events.
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